10 Most Undervalued Biotech Stocks to Buy Now

6. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Forward P/E: 8.68

Number of Hedge Fund Holders: 27

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the top most undervalued biotech stocks to buy now. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on August 6, setting a price target of $70.00.

The analyst told investors that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has continuously advancing pipeline programs and has exhibited consistent commercial execution, suggesting resilient growth.

This holds especially true for its product WAKIX, which has shown solid revenue growth and expanded its prescriber base.

The analyst also reasoned that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has a solid financial position with reaffirmed revenue guidance and considerable cash reserves, positioning it to pursue and self-fund growth opportunities.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders.

Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.